Skip to main content
. 2010 Dec;21(6):342–343.

Table 1. 1BASELINE DEMOGRAPHICS.

Rivaroxaban (n = 7 081) Warfarin (n = 7 090)
CHADS2 score (mean) 3.48 3.46
2 (%) 13 13
3 (%) 43 44
4 (%) 29 28
5 (%) 13 12
6 (%) 2 2
Prior VKA use (%) 62 63
Congestive heart failure 63 62
Hypertension (%) 90 91
Diabetes mellitus (%) 40 39
Prior stroke/TIA/embolism (%) 55 55
Prior myocardial infarction (%) 17 18

Based on intention-to-treat population